Geron Corp
GERN
查看详细走势图
1.530USD
+0.070+4.79%
收盘 02/06, 16:00（美东）报价延迟15分钟
976.68M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+4.79%
5天
+11.68%
1月
+11.68%
6月
+17.69%
今年开始到现在
+15.91%
1年
-47.78%
查看详细走势图
TradingKey Geron Corp股票评分
单位: USD 更新时间: 2026-02-06操作建议
Geron Corp当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名39/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价3.17。中期看，股价处于上升通道。近一个月，市场表现较强，技术面和基本面综合得分较高，较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Geron Corp评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Geron Corp亮点
亮点风险
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
业绩高增长
公司营业收入稳步增长，连续3年增长12818.46%
业绩增长期
公司处于发展阶段，最新年度总收入76.99M美元
利润高增长
公司净利润处于行业前列，最新年度总收入76.99M美元
估值低估
公司最新PE估值-12.85，处于3年历史低位
机构减仓
最新机构持股517.62M股，环比减少29.75%
乔尔·格林布拉特持仓
明星投资者乔尔·格林布拉特持仓，最新持仓市值38.83K
分析师目标
根据
7
位分析师
买入
评级
3.167
目标均价
+115.42%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Geron Corp新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Geron Corp简介
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
公司代码GERN
公司Geron Corp
CEOSemerjian (Harout)
网址https://www.geron.com/
相关品种
